Giving Thanks for Clear NEOPLASM Documentation
November 19, 2026 | 12:30–1:30 PM EST
Documentation & Coding: Active Disease vs. Personal History
This season, give thanks for clear documentation! Join ERM Consulting for Giving Thanks for Clear NEOPLASM Documentation, a Lunch & Learn focused on strengthening neoplasm documentation and coding.
We’ll carve through common documentation challenges, clarify the distinction between active malignancy and personal history, and explore how treatment status and clinical details support accurate ICD-10-CM coding and HCC capture. Through realistic clinical scenarios, you’ll gain practical strategies to avoid common pitfalls and ensure documentation reflects the patient’s current condition.
Bring your lunch, feast on practical knowledge, and earn 1 AAPC CEU!
Session Objectives
- Distinguish active malignancy from personal history of malignancy.
- Determine how treatment status affects diagnosis selection.
- Recognize documentation needed for primary, secondary, recurrent, and remitted disease.
- Reduce coding errors involving uncertain or unsupported cancer status.
Agenda
12:30–12:35 PM — Welcome and Session Overview
- Learning objectives
- Why accurate cancer-status documentation matters
12:35–12:47 PM — Defining Neoplasm Status
- Active malignancy
- Personal history of malignancy
- Remission, recurrence, and residual disease
- Primary versus metastatic disease
12:47–1:00 PM — Documentation and Coding Essentials
- Documenting the primary site, laterality, and histology when known
- Current treatment and its effect on code selection
- Secondary malignant neoplasms and metastatic sites
- Encounters for treatment, routine surveillance, and follow-up care
1:00–1:10 PM — HCC and Risk-Adjustment Considerations
- When malignancy may be reported as active
- Evidence supporting current disease status
- Avoiding inappropriate reporting of resolved or historical cancers
- Distinguishing active monitoring from treatment of active disease
1:10–1:22 PM — Case Studies and Common Errors
- Completed treatment with no evidence of disease
- Long-term hormonal or maintenance therapy
- Recurrent and metastatic cancer
- Ambiguous documentation of cancer status
1:22–1:25 PM — Key Takeaways and Practical Recommendations
1:25–1:30 PM — Questions and Answers
Bring the TEAM (3+) and save 10% on virtual events.
Do you need an invoice? If so, please email orders@ermconsultinginc.com.
Questions? Please call Todd Gifford at 772-267-8156
View our website for additional information and full list of upcoming events - www.ermconsultinginc.com
